Diligence memo · auto-generated · as of July 2, 2026
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Aer Therapeutics, Inc. operates in Biotechnology, based in RALEIGH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aer Therapeutics, Inc. has raised $21M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2022-12-09.
Most recent recorded round closed around 2025-01-24.
Valuation (modeled)modeled
Provath models Aer Therapeutics, Inc. at approximately $28M (range $10M–$45M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.36× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 26 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 3.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).
Modeled value ranks above 34% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.